A top official at pharmaceutical giant Johnson & Johnson dismissed questions on a recent earnings call about the drug price reform debate in Washington, saying that the company is “responsible” in its pricing.
As part of the question and answer period during the company’s third quarter earnings call in October, one questioner asked Johnson & Johnson Chief Financial Officer Dominic Caruso where he sees the drug pricing reform debate in Washington going and if the company was planning a pledge, similar to one made by many firms in the 1990s, to not raise drug prices beyond the cost of inflation. Continue reading